Madrigal Pharmaceuticals Inc
NASDAQ:MDGL
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL
Price:
447.72
USD
1.49%
Market Closed
Market Cap:
$10.3B
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL
|
US |
Relative Value
The Relative Value of one
MDGL
stock under the Base Case scenario is
529.65
USD.
Compared to the current market price of 447.72 USD,
Madrigal Pharmaceuticals Inc
is
Undervalued by 15%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
MDGL
Relative Value
Base Case
529.65
USD
Undervaluation 15%
Multiples Across Competitors
MDGL Competitors Multiples
Madrigal Pharmaceuticals Inc Competitors
Madrigal Pharmaceuticals Inc Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| US |
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL
|
10.2B USD | 10.6 | -35.4 | -32.3 | -32.2 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | 33 690 872.8 | -160 127.7 | -194 446.1 | -192 227.3 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
362.3B USD | 5.9 | 86.5 | 14.4 | 20 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
188.5B USD | 5.1 | 24.4 | 14.2 | 14.2 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
170.4B USD | 5.8 | 20 | 12.5 | 15.5 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
114.6B USD | 9.5 | 29 | 21.8 | 22.8 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | 2 091 | -533.6 | -581 | -565.5 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
77.9B USD | 5.4 | 17.3 | 12.7 | 14.5 | |
| AU |
|
CSL Ltd
ASX:CSL
|
67.4B AUD | 3.1 | 34.4 | 11.4 | 14.3 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | 20.1 | -61.8 | -66.6 | -60.1 | |
| US |
|
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
|
40.6B USD | 10.9 | 129.6 | 72.5 | 80.5 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
